Læknablaðið - 01.04.2014, Blaðsíða 24

224 LÆKNAblaðið 2014/100
R A N N S Ó K N
38. Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ.
Impact of Vacuum-Assisted Closure (VAC) Therapy
on Clinical Outcomes of Patients with Sternal Wound
Infections: A Meta-Analysis of Non-Randomized Studies.
PLoS One 2013; 8: e64741.
39. Steingrímsson S, Gustafsson R, Gudbjartsson T, Mokhtari
A, Ingemansson R, Sjögren J. Sternocutaneous fistulas
after cardiac surgery: incidence and late outcome during a
ten-year follow-up. Ann Thorac Surg 2009; 88: 1910-5.
40. Steingrímsson S, Sjögren J, Gudbjartsson T. Incidence of
sternocutaneous fistulas following open heart surgery in a
nationwide cohort. Scand J Infect Dis 2012; 44: 623-5.
41. Carr JA. Abdominal compartment syndrome: a decade of
progress. J Am Coll Surg 2013; 216: 135-46.
42. Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R,
Malbrain ML, De Keulenaer B, et al. Intra-abdominal
hypertension and the abdominal compartment syndrome:
updated consensus definitions and clinical practice
guidelines from the World Society of the Abdominal
Compartment Syndrome. Intensive Care Med 2013; 39:
1190-206.
43. Carlson GL, Patrick H, Amin AI, McPherson G,
MacLennan G, Afolabi E, et al. Management of the open
abdomen: a national study of clinical outcome and safety
of negative pressure wound therapy. Ann Surg 2013; 257:
1154-9.
44. Bjarnason T, Montgomery A, Ekberg O, Acosta S, Svensson
M, Wanhainen A, Björck M, Petersson U. One-year follow-
up after open abdomen therapy with vacuum-assisted
wound closure and mash-mediated fascial traction. World
J Surg 2013; 37: 2031-8.
45. Roberts DJ, Zygun DA, Grendar J, Ball CG, Robertson HL,
Ouellet JF, et al. Negative-pressure wound therapy for
critically ill adults with open abdominal wounds: a sys-
tematic review. J Trauma Acute Care Surg 2012; 73: 629-39.
46. Moisidis E, Heath T, Boorer C, Ho K, Deva AK. A pro-
spective, blinded, randomized, controlled clinical trial
of topical negative pressure use in skin grafting. Plast
Reconstr Surg 2004; 114: 917-22.
47. de Laat EH, van den Boogaard MH, Spauwen PH, van
Kuppevelt DH, van Goor H, Schoonhoven L. Faster
wound healing with topical negative pressure therapy
in difficult-to-heal wounds: a prospective randomized
controlled trial. Ann Plast Surg 2011; 67: 626-31.
48. Wedemeyer J, Schneider A, Manns MP, Jackobs S.
Endoscopic vacuum-assisted closure of upper intestinal
anastomotic leaks. Gastrointest Endosc 2008; 67: 708-11.
49. Weidenhagen R, Hartl WH, Gruetzner KU, Eichhorn ME,
Spelsberg F, Jauch KW. Anastomotic leakage after esop-
hageal resection: new treatment options by endoluminal
vacuum therapy. Ann Thorac Surg 2010; 90: 1674-81.
50. Arezzo A, Miegge A, Garbarini A, Morino M. Endoluminal
vacuum therapy for anastomotic leaks after rectal surgery.
Tech Coloproctol 2010; 14: 279-81.
51. Leininger BE, Rasmussen TE, Smith DL, Jenkins DH,
Coppola C. Experience with VAC and delayed primary
closure of contaminated soft tissue injuries in Iraq. J
Trauma 2006; 61: 1207-11.
52. Gudbjartsson T, Sigurdsson H, Sigurdsson E, Kjartansson
J. Vacuum-assisted closure for successfull treatment of a
major contaminated gunshot chest-wound: A case report.
Eur J Trauma Emerg Surg 2008; 34: 508-10.
53. Contractor D, Amling J, Brandoli C, Tosi LL. Negative
pressure wound therapy with reticulated open cell foam
in children: an overview. J Orthop Trauma 2008; 22 (10
Suppl): S167-76.
54. Sartipy U, Lockowandt U, Gäbel J, Jidéus L, Dellgren G.
Cardiac rupture during vacuum-assisted closure therapy.
Ann Thorac Surg 2006; 82: 1110-1.
55. Vowden K, Téot L, Vowden P. Selecting topical nega-
tive pressure therapy in practice. European Wound
Management Association (EWMA). Position Document:
Topical negative pressure in wound management. MEP
Ltd, London 2007: 10-4.
56. Argenta LC, Morykwas MJ, Marks MW, DeFranzo AJ,
Molnar JA, David LR. Vacuum-assisted closure: state of
clinic art. Plast Reconstr Surg 2006; 117 (7 Suppl): 127s-42s.
57. Sjögren J, Gustafsson R, Nilsson J, Lindstedt S, Nozohoor
S, Ingemansson R. Negative-pressure wound therapy
following cardiac surgery: bleeding complications and
30-day mortality in 176 patients with deep sternal wound
infection. Interact Cardiovasc Thorac Surg 2011; 12: 117-20.
58. Petzina R, Malmsjö M, Stamm C, Hetzer R. Major comp-
lications during negative pressure wound therapy in post-
sternotomy mediastinitis after cardiac surgery. J Thorac
Cardiovasc Surg 2010; 140: 1133-6.
59. Thorsteinsson DT, Valsson F, Geirsson A, Gudbjartsson
T. Major cardiac rupture following surgical treatment for
deep sternal wound infection. Interact Cardiovasc Thorac
Surg 2013; 16: 708-9.
60. Jones GA, Butler J, Lieberman I, Schlenk R. Negative-
pressure wound therapy in the treatment of complex post-
operative spinal wound infections: complications and les-
sons learned using vacuum-assisted closure. J Neurosurg
Spine 2007; 6: 407-11.
61. White RA, Miki RA, Kazmier P, Anglen JO. Vacuum-
assisted closure complicated by erosion and hemorrhage
of the anterior tibial artery. J Orthop Trauma 2005; 19: 56-9.
62. Malli S. Keep a close eye on vacuum-assisted wound
closure. Nursing 2005; 35: 25.
63. Ford-Dunn S. Use of vacuum assisted closure therapy in
the palliation of a malignant wound. Palliat Med 2006; 20:
477-8.
64. Attinger CE, Janis JE, Steinberg J, Schwartz J, Al-Attar A,
Couch K. Clinical approach to wounds: debridement and
wound bed preparation including the use of dressings and
wound-healing adjuvants. Plast Reconstr Surg 2006; 117(7
Suppl): 72s-109s.
65. Bee TK, Croce MA, Magnotti LJ, Zarzaur BL, Maish GO,
Minard G, et al. Temporary abdominal closure techniques:
a prospective randomized trial comparing polyglactin 910
mesh and vacuum-assisted closure. J Trauma 2008; 65: 337-
42; discussion 42-4.
66. National Institute for Health and Care Excellence.
Negative pressure wound therapy for the open abdo-
men. IPG467. National Institute for Health and Care
Excellence, London 2009. nice.org.uk/nicemedia/
live/14315/65841/65841.pdf. – febrúar 2014.
67. Apelqvist J, Armstrong DG, Lavery LA, Boulton AJ.
Resource utilization and economic costs of care based on
a randomized trial of vacuum-assisted closure therapy in
the treatment of diabetic foot wounds. Am J Surg 2008; 195:
782-8.
68. Mouës CM, van den Bemd GJ, Meerding WJ, Hovius
SE. An economic evaluation of the use of TNP on full-
thickness wounds. J Wound Care 2005; 14: 224-7.
69. Guðmundsdóttir I, Steingrímsson S, Guðbjartsson
T. Sárasogsmeðferð á Íslandi - notkun og árangur.
Læknablaðið 2012; 98: 149-53.
ENGLISH SUMMARY
Negative pressure wound therapy (NPWT) is a new therapeutic option
in wound healing and was first described in its present form in 1997. A
vacuum source is used to create sub-atmospheric pressure in the local
wound environment to promote healing. This is achieved by connecting
a vacuum pump to a tube that is threaded into a wound gauze or foam
filler dressing covered with a drape. This concept in wound treatment
has been shown to be useful in treating different wound infections,
including diabetic wounds as well as complex infections of the abdomen
and thorax. NPWT has been used in Iceland for over a decade and its
use is steadily increasing. This review describes the indications and
outcome of NPWT and is aimed at a broad group of doctors and nurses
where recent Icelandic studies on the subject are covered.
negative pressure wound therapy – review
Ingibjorg Gudmundsdottir1, Steinn Steingrimsson1, Elsa Valsdottir1,2, Tomas Gudbjartsson1,2
key words: Negative pressure wound therapy (NPWT), vacuum assisted closure, wound infection, treatment, outcome, review.
Correspondence: Tómas Guðbjartsson, tomasgud@landspitali.is
1Department of Surgery, Landspitali University Hospital, 2Faculty of Medicine, University of Iceland.

TARGIN ® ábe
2
Eina sterka ópíóíð lyfið sem vinnur einnig
gegn hægðatregðu af völdum ópíóíða1
Takið aukaverkanir við meðhöndlun mikilla verkja alvarlega!
TARGIN ® ábending: Miklir verkir sem ekki næst nægileg stjórn á nema með ópíóíð
verkjalyfjum. Ópíóíð mótlyfinu naloxóni er bætt í til að vinna gegn hægðatregðu af völdum
ópíóíða með því að blokka verkun oxýkódons við ópíóíð viðtaka staðbundið í þörmum2
TARGIN ® er með skilyrta greiðsluþátttöku SÍ. Sækja má um lyfjaskírteini fyrir sjúklinga
með alvarlega verki sem krefjast ópíóíðmeðferðar og hægðatregðu af völdum ópíóíða.
1. Clemens et al. Expert Opin. Pharmacother; 11(2): 1-14, 2010
2. Sérlyfjaskrá
LD
11
31
10
1
Norpharma a/s
Slotsmarken 15
2970 Hørsholm
Meðhöndlun
mikilla verkja
Hægðatregða af
völdum ópíóíða